- $289.46bn
- $331.15bn
- $56.33bn
European shares dip as rise in oil prices weighs; Novartis slips
Novartis shares down as failed cholesterol drug study increases pipeline pressure
Novartis slips as its drug fails to cut heart attack, stroke risk in late-stage trial
Swiss stocks - Factors to watch on September 7
Brief: Royalty Pharma Announces Update On Novartis’ Phase 3 Topline Results For Pelacarsen
Novartis, Ionis' experimental heart drug misses key goal in closely watched trial (updated)
Ionis-Novartis heart drug misses main goal of late-stage trial
Novartis could cut about 130 jobs in Basel site relocation (updated)
Novartis could cut around 130 jobs in Switzerland
Novartis signs deal worth up to $3.2 billion for Alteogen's drug delivery technology
Europe's STOXX 600 hits one-month low as inflation, rising yields pressure markets (updated)
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Oxford BioMedica slides as Novartis, Bristol-Myers Squibb pause CAR-T autoimmune trials
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Brief: Bristol-Myers Spokesperson Says Co Implemented A Voluntary Pause To Review Clinical Data Across Their Zola-Cel Program
Novartis gains after positive late-stage MS drug trial data
Corrected: UPDATE 2-Novartis MS pill beats older drug in trials, boosts pipeline hopes
Brief: Novartis Temporarily Pausing Screening, Randomization And Treatment Across Rapcabtagene Autoleucel Trials In Autoimmune Diseases
Novartis' oral multiple sclerosis drug meets main goal in late stage studies